Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags 33A

Tag: 33A

U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine

Peter Hofland
The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...

Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...

Peter Hofland
Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...

Study Shows 76% Objective Response Rate in Newly Diagnosed Acute Myeloid...

Peter Hofland
Phase I clinical data from a study evaluating vadastuximab talirine, also known as SGN-CD33A or 33A in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in...

Pivotal Trial with Vadastuximab Talirine Initiated for Treatment of Patients with...

Peter Hofland
A phase III study called CASCADE, designed to evaluate Seattle Genetics' vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) or decitabine (Dacogen) has...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X